8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

Current Report Pursuant to Section 13 or 15(d) of

the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 1, 2013

ROCHESTER MEDICAL CORPORATION

(Exact name of registrant as specified in its charter)

Minnesota	0-18933	41-1613227
(State or other jurisdiction of incorporation)	(Commission file number)	(I.R.S. Employer Identification No.)

One Rochester Medical Drive, Stewartville, MN 55976

(Address of principal executive offices)

Registrant’s telephone number, including area code:  (507) 533-9600

Not Applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 7.01.Regulation FD Disclosure.

The following information is being “furnished” in accordance with General Instruction B.2 of Form 8-K and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed to be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

Furnished herewith as Exhibit 99.1 and incorporated by reference herein is a copy of presentation materials prepared by Rochester Medical Corporation for use at investor conferences.

Item 9.01.Financial Statements and Exhibits.

(d) Exhibits.

Reference is made to the Exhibit Index hereto with respect to the exhibits furnished herewith.  The exhibits listed in the Exhibit Index hereto are being “furnished” in accordance with General Instruction B.2 of Form 8-K and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed to be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

2

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.

Date:August 1, 2013

ROCHESTER MEDICAL CORPORATION
By:	/s/ David A. Jonas
	David A. Jonas
	Chief Financial Officer

3

EXHIBIT INDEX

Exhibit No.	Description
99.1	Presentation materials prepared by Rochester Medical Corporation

4

EX-99.1

Exhibit 99.1

Summer 2013 Rochester Medical Corporation Investor Presentation

Outline . Company Overview . Investment Considerations . Global Revenue Growth Trend . Sound Growth Strategy . Market Opportunity & Product Lines . Financial Summary & Outlook 2

Company Overview . Founded in 1988 . Develop, manufacture and market innovative disposable incontinence and bladder drainage products . Advanced technology company with deep & growing patent portfolio . Vertically integrated with strong R&D and proprietary manufacturing capabilities . Global sales & distribution presence with focus in North America and Europe . Private label supplier to leading medical device companies *YTD Fiscal 2013 revenues exclude Foley sales YTD FY'13* Private Label US Direct OUS Direct 3

Investment Considerations . Mid-teens revenue growth & doubling of net income this fiscal year . Superior technologies enable market share gains in large global markets . Favorable reimbursement changes support our technologies . Seasoned US sales team & broad international distribution . Recent divestiture strengthens profitability . Strong balance sheet & cash flow generation . Material equity ownership by management team 4

Global Revenue Growth: Driven by Accelerating Direct Sales, US & OUS *F09 if £ to $ exchange rates had not fallen (1.966 – 1.558) 5 $0 $10 $20 $30 $40 $50 $60 $70 FY05 FY06 FY07 FY08 FY09* FY10 FY11 FY12 FY13E Direct Sales: Non-Foley Private Label Direct Sales: Foley

Sound Growth Strategy: Drive Sales, Profit & Cash Flow Improvements . Deliver mid-teens top-line growth* . Paced by robust U.S. and U.K. Direct Sales growth, up 18% and 23%, respectively, year-to-date fiscal 2013 . Other international Direct Sales markets growing modestly . Moderate Private Label sales growth . Improve profitability . Fixed cost leverage & reduced operating expense . Divestiture of unprofitable Foley business . Product mix shift to Direct Sales . Generate increased cash flow . Internally fund projected growth . Expand manufacturing capacity 6 *Excluding sales of Foley catheters in Fiscal 2012 and Fiscal 2013

Global Market Opportunities: Superior Products Drive Share Capture (US$, millions) Product U.S. Market Europe Market Total Global Market Estimated Market 5 Year CAGR (%) ROCM Global Market Share (%) Key Competitors Intermittent Catheters $400 $400 $800 Low single digits <3% Coloplast, Hollister Male External Catheters $50 $78 $128 Low single digits <20%* Coloplast, Hollister Total: $450 $478 $928 Low single digits 7 *MEC unit share approximates 30% while dollar share is lower due to transfer pricing variations.

Innovative Products Products Features & Benefits Intermittent Catheters Magic3 & Hydrosil • 3-layer construction enables soft, gentle outer layer with firm inner layer for easy insertion & removal • Silicone (non-latex) • Hydrophilic, antibacterial & phthalate-free Male External Catheters Spirit™ Hydrocolloid Adhesive Sheath • Advanced adhesive innovations • New product introductions expand market • Silicone plus Hydrocolloid adhesive aids skin integrity FemSoft Insert • Elegant, non-surgical solution to female stress incontinence • Powerful clinician and patient testimonials 8

Intermittent Catheters 9 . Biggest growth driver for Rochester Medical . Gaining share in $800 million growing worldwide market

Male External Catheters 10 . Latex free . Skin-friendly advanced adhesive innovations . Wide array of styles and sizes offers security, confidence and convenience . Spirit™ launched October 2012 . First and only male external catheter to combine the moisture-wicking properties of a hydrocolloid adhesive with the superior breathability of silicone

FemSoft Insert . An elegant & proprietary solution for female stress incontinence . Stress incontinence affects 14 million women in the U.S. . Very positive response from OB/GYNs & urologists . Compelling testimonials from consumers . “FemSoft saved my life!” 11 . U.S. and U.K. reimbursement coverage granted . Guidance assumes very modest FemSoft revenue . “(FemSoft) will give you your freedom back.”

Favorable Market Dynamics: Support Growth & Share Gains Products Key Market Drivers Intermittent Catheters • New product features offer measureable patient benefits & attract clinician support • Change in U.S. reimbursement in 2009 allowing 200 catheters/month, up from 4/month • International penetration Male External Catheters • Skin-friendly advanced adhesive innovations • International penetration FemSoft Insert • Increasing awareness of FemSoft as non-surgical solution to a leading women’s health issue • Favorable U.K. reimbursement 12

Sound Growth Strategy: Major U.S. Sales Force & OUS Presence . Significant U.S. Home Care sales infrastructure . ~21 reps today vs. 3 in 2010 . Steadily increasing share of scripts written • We estimate 1 of every 4 new long-term patient scripts written for Rochester brand product . Direct sales presence in the U.K. and the Netherlands . United Kingdom: 29 reps . Netherlands: 12 reps . Germany: 2 reps by year-end 2013 (revenue expected in FY’14) . Broad distribution presence in continental Europe and emerging markets (i.e., Asia/Pacific, Latin America) 13

U.S. Sales Force Coverage = One sales rep = One regional sales manager 14

Sound Growth Strategy: Expand Internationally to Drive OUS Sales . Drive organic growth in existing international markets . Primary markets: Europe & Middle East . Direct sales force located in the U.K. & the Netherlands . Extensive distributor network outside the U.K. . Partnered with Teleflex to sell our branded products . Recently established a small, direct sales force in Germany . The largest home care market in Europe . Explore accretive acquisitions . To access new markets and/or expand product lines 15

Blue shading denotes Rochester Medical Direct Sales activity LTM Distribution relationships in 58 countries Rochester Medical-manufactured products marketed in more than 75 countries 16 Global Sales & Distribution: International Sales – 63% of FY12 Total Sales

Sound Growth Strategy: Private Label a Steady Grower . Solid relationships with leading medical products customers around the world . Coloplast . Hollister . B. Braun . Quarterly fluctuations in sales growth will diminish as Private-label sales represent a smaller % of total sales 17 YTD FY'13* Private Label Direct FY10 Private Label Direct *YTD Fiscal 2013 revenues exclude Foley sales

Sound Growth Strategy: Divestiture of Foley Catheter Line . Rationale for divestiture: to be a stronger, faster growing & more profitable company . High barriers in Foley market . Extensive manufacturing & marketing costs reduced operating income . Financial implications of divestiture . Near-term: limited impact – approx. $500,000 in shut-down costs . Longer-term: higher gross margins, substantially lower operating expenses and at least $3 million in incremental operating profit 18

Recent Quarterly Results (as of 6/30/13) 19 FY End September 3 Months 9 Months (US$, millions) Q3’13 Q3’12 Change FY’13 FY’12 Change Revenues(1) $17.0 $15.4 10% $50.9 $44.8 14% Gross Margin 51.0% 49.6% +140bps 50.2% 49.9% +30bps Operating Expenses $6.9 $6.9 -- $20.6 $20.8 -1% Operating Income $1.7 $0.7 145% $4.9 $1.5 221% Net Income $1.1 $0.5 128% $3.3 $1.0 227% Diluted EPS $0.09 $0.04 120% $0.09 $0.04 120% (1)Revenue presented on an as reported basis. Q3’13 revenue growth was 11% on a constant currency basis. 9 months FY’13 revenue growth was 14.1% on a constant currency basis.

Third Quarter 2013 Highlights . Total Global sales increased 18%* y/y to $17.0 million . Global Direct Sales up 22%* y/y to $13.5 million . Intermittent Catheters up 34% y/y . MECs up 36% y/y . Global Private Label Sales up 5% y/y $3.3 million . GAAP Net Income of $1.1 million ($0.09 per diluted share) compared to $0.5 million ($0.04 per diluted share) in FY12 . The U.S. Direct reported 30%* growth and U.K. Direct reported 26%* growth compared to the prior year period . Private Label business remains a steady contributor and is performing nicely in line with our expectations . The Rochester Medical growth story is solidly on track with our expectations 20 *In constant currency; excludes the effects of the exit from the Foley business.

Financial Profile (as of 6/30/13) . Strong balance sheet . $26.2 million in cash & marketable securities . $15.4 million working capital (excluding cash) . $5 million available on a $5 million Line of Credit . Zero debt . Positive free cash flow .Will fully-fund construction of new manufacturing facility with internally generated cash flow from operations in FY13 . Share repurchase plan availability 21

Looking Ahead . FY13 guidance(excluding Foley Business): . $67 million in revenues, up 17%* . $7 million in after-tax net income** . Expect strong direct Home Care sales growth . Primarily driven by Intermittent Catheter products . U.S. & U.K. strongest growth, complemented by more moderate Europe/ROW growth . Expect stable Private Label sales growth . Innovative new products under development . Expect solid profitability to continue to improve 22 *Excludes Foley catheter sales in both period. **Includes $150,000 in medical device excise tax in G&A.

Summary . Rochester Medical is focused on delivering solid top line growth and improving profitability . Clear strategy to grow sales . Highly advanced & innovative product portfolio with further advanced products in the pipeline . Large, global markets with opportunities to gain abundant market share . Strong global sales and distribution platform supports the strategy . Key sources of operating margin improvement identified and underway . Healthy balance sheet 23

Forward Looking Statements This presentation contains “forward-looking statements” with in the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about future financial and operating results of Rochester Medical. Such statements are based on currently available information, operating plans and management’s expectations about future events and trends. Such statements inherently involve significant risks and uncertainties that could cause actual results to differ materially from those predicted in such forward-looking statements, including the uncertainty of estimated revenues and profits, the uncertainty of current domestic and international economic conditions that could adversely affect the level of demand for the Company’s products and increased volatility in foreign exchange rates, the uncertainty of market acceptance of new product introductions, and our level of success in marketing our Rochester Medical branded products, the uncertainty of gaining new strategic relationships or locating and capitalizing on strategic opportunities, the uncertainty of timing of Private Label Sales revenues (particularly international customers), FDA and other regulatory review and response times, and other risk factors listed from time to time in the Company’s SEC reports and filings, including, without limitation, the section entitled “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended September 30, 2012, and quarterly reports on Forms 10-Q. Readers are cautioned not to place undue reliance on any such forward-looking statements, which speak only as of the date they are made. The Company undertakes no obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise. 24

[LOGO]